Aggrastat Injection Premixed (HCPCS code J3246) is a clear, non-preserved, sterile solution premixed in a vehicle made iso-osmotic with 0.9%
Dimensions (box size)
15 mL Bolus Vial
3.75 mg in 15 mL
2.6" H x 1.7" W x 1.6" D
(contains 1 ready-to-use vial)
100 mL Bag
5 mg in 100 mL
11.8" H x 5.8" W x 1.1" D
250 mL Bag
12.5 mg in 250 mL
12.8" H x 6.3" W x 1.7" D
Aggrastat is available through normal distribution at your wholesaler. For immediate supply, Aggrastat is available as a drop shipment via Express Overnight Delivery. It is important to provide your wholesaler with updated demand forecasts for Aggrastat.
Download or request Aggrastat’s resources for your hospital.
Indication: AGGRASTAT® is a platelet aggregation inhibitor indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
IMPORTANT SAFETY INFORMATION
Known hypersensitivity to any component of Aggrastat.
History of thrombocytopenia with prior exposure to Aggrastat.
Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within the previous month.
Warnings and Precautions:
Bleeding is the most common complication encountered during therapy with AGGRASTAT. Most bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization. Minimize the use of traumatic or potentially traumatic procedures such as arterial and venous punctures, intramuscular injections, nasotracheal intubation, etc. Concomitant use of fibrinolytics, oral anticoagulants and antiplatelet drugs increases the risk of bleeding.
Bleeding is the most commonly reported adverse reaction.